Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda Commits Up to US$30 Million to Indonesia Plasma Partnership
July 14, 2026
- Padcev/Keytruda Bags Expanded US Nod in Perioperative MIBC
July 14, 2026
- Olumiant Oral Suspension Now Available in Japan: Lilly/Incyte
July 14, 2026
- Japan Pharma Market Grows 3.8% in FY2025 as Protected Brands Shine: IQVIA
July 13, 2026
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
- Expert Welcomes Talvey-Tecvayli Combo for Difficult-to-Treat MM
July 10, 2026
- Axcelead Teams Up with Mitsubishi to Expand Drug Discovery Support Biz
July 10, 2026
- Roche PD-L1 Test Approved for Imfinzi in Endometrial Cancer
July 10, 2026
- Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
- Towa Seeks Policy Reset on Off-Patent Meds, Says Generic Push Has Run Its Course
July 9, 2026
- Ipsen Rolls Out Japan’s First FOP Treatment Sohonos
July 9, 2026
- Fujifilm Picked for FDA Pilot to Accelerate US CDMO Expansion
July 9, 2026
- Nichi-Iko Exits Turnaround Mode, Eyes Next Growth Phase
July 9, 2026
- AstraZeneca CSO Urges Global Drug Price “Rebalancing” amid MFN Push
July 8, 2026
- JB to Build New Plant in Hokkaido to Double Ig Production
July 8, 2026
- Padcev/Keytruda Accepted for China Review in Perioperative MIBC
July 8, 2026
- Japan Ethical Drug Sales Fall 1.1% in May: Crecon
July 8, 2026
- Astellas Confirms Applying to US MFN Medicaid Pricing Model
July 7, 2026
- Otsuka’s Astex Inks Breast Cancer R&D Pact with Genentech
July 7, 2026
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…